IVBM All Coverage | Value-Based Medicine News

Telehealth provides more flexibility for patients with gastrointestinal issues to better fit their care into their lives and around symptoms they may be experiencing, said Sam Holliday, co-founder and CEO of Oshi Health.

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.

David A. Eagle, MD, New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment.

A panel of experts discussed the explosion of information and advances in cancer genomics and the accompanying challenges of understanding the data and taking action.

Guideline-directed cancer care—with help from a clinical support tool—can close disparities while reducing costs more efficiently than other means, such as prior authorization.

Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.

Ishani Ganguli, MD, MPH, assistant professor of medicine at Harvard Medical School, physician at Brigham and Women’s Hospital, reacts to receiving the 2022 Seema S. Sonnad Emerging Leader in Managed Care Research Award.

Population health brings an important lens to both oncology practice and research, said Neil Iyengar, MD, associate attending physician, breast medical service, Memorial Sloan Kettering Cancer Center.

The Enhancing Oncology Model (EOM) will be the successor to the Oncology Care Model.

Co-hosted by Memorial Sloan Kettering Cancer Center, the most recent Institute for Value-Based Medicine® event took place on September 22, with a focus on improving cancer care delivery through innovation.

Ty J. Gluckman, MD, FACC, FAHA, who is medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, addressed the 2022 Congress of the American Society for Preventive Cardiology meeting in Louisville, Kentucky.

At a panel for the National Health Alliance, 3 experts talked about incorporating patient needs and requests in cancer care.

Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute (FCSRI), discusses what guests can expect at the in-person Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by FCSRI.

Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, previews the Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), cohosted by Florida Cancer Specialists & Research Institute.

With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.

The administration said it would make the results of its drug price negotiations with manufacturers, as well as its approach to value-based care models, open to a variety of payers.

The specialization program will teach fundamentals and offer real-world examples of value-based care through an online program.

Value-based insurance design has made gains in oncology, but there's more work to do.

Panelists highlight approaches for integrating behavioral and physical health into a whole-patient model and discuss emerging opportunities for the integration of behavioral mental health in value-based care.

The recent focus on disparities in health care comes through in the call to action.

An HHS report outlines efforts to reduce kidney failure and increase options such as home-based dialysis. COVID-19 has made kidney care a higher priority.

In a webinar, experts outlined challenges providers face amid the coronavirus disease 2019 (COVID-19) pandemic and the benefits of increased access to high-value care during the outbreak and beyond.

A study looking at the ways in which different countries handle appraisal and reimbursement processes for rare disease treatments (RDTs) revealed that implementing supplemental processes can aid in patient and physician decision making.